Skip NavigationSkip to Content

Severe COVID-19 Is Characterized by an Impaired Type I Interferon Response and Elevated Levels of Arginase Producing Granulocytic Myeloid Derived Suppressor Cells

  1. Author:
    Dean, Matthew J
    Ochoa, Juan B
    Sanchez-Pino, Maria Dulfary
    Zabaleta, Jovanny
    Garai, Jone
    Del Valle, Luis
    Wyczechowska, Dorota
    Baiamonte, Lyndsey Buckner
    Philbrook, Phaethon
    Majumder, Rinku
    Vander Heide, Richard S
    Dunkenberger, Logan
    Thylur, Ramesh Puttalingaiah
    Nossaman, Bobby
    Roberts, W Mark
    Chapple, Andrew G
    Wu, Jiande
    Hicks, Chindo
    Collins,Jack
    Luke,Brian
    Johnson,Randy
    Koul, Hari K
    Rees, Chris A
    Morris, Claudia R
    Garcia-Diaz, Julia
    Ochoa, Augusto C
  2. Author Address

    Louisiana State University Cancer Center, New Orleans, LA, United States., Department of Surgery, Ochsner Medical Center, New Orleans, LA, United States., Department of Genetics, LSU Health, New Orleans, LA, United States., Department of Pediatrics, LSU Health, New Orleans, LA, United States., Department of Pathology LSU Health, New Orleans, LA, United States., Tissue Biorepository, Ochsner Medical Center, New Orleans, LA, United States., Department of Biochemistry, LSU Health, New Orleans, LA, United States., Department of Internal Medicine, Ochsner Medical Center, New Orleans, LA, United States., School of Public Health, LSU Health, New Orleans, LA, United States., Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, United States., Division of Emergency Medicine, Boston Children 39;s Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA, United States., Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, Children 39;s Healthcare of Atlanta, Atlanta, GA, United States.,
    1. Year: 2021
    2. Date: Jul 14
    3. Epub Date: 2021 07 14
  1. Journal: Frontiers in immunology
    1. 12
    2. Pages: 695972
  2. Type of Article: Article
  3. Article Number: 695972
  4. ISSN: 1664-3224
  1. Abstract:

    COVID-19 ranges from asymptomatic in 35% of cases to severe in 20% of patients. Differences in the type and degree of inflammation appear to determine the severity of the disease. Recent reports show an increase in circulating monocytic-myeloid-derived suppressor cells (M-MDSC) in severe COVID 19 that deplete arginine but are not associated with respiratory complications. Our data shows that differences in the type, function and transcriptome of granulocytic-MDSC (G-MDSC) may in part explain the severity COVID-19, in particular the association with pulmonary complications. Large infiltrates by Arginase 1+ G-MDSC (Arg+G-MDSC), expressing NOX-1 and NOX-2 (important for production of reactive oxygen species) were found in the lungs of patients who died from COVID-19 complications. Increased circulating Arg+G-MDSC depleted arginine, which impaired T cell receptor and endothelial cell function. Transcriptomic signatures of G-MDSC from patients with different stages of COVID-19, revealed that asymptomatic patients had increased expression of pathways and genes associated with type I interferon (IFN), while patients with severe COVID-19 had increased expression of genes associated with arginase production, and granulocyte degranulation and function. These results suggest that asymptomatic patients develop a protective type I IFN response, while patients with severe COVID-19 have an increased inflammatory response that depletes arginine, impairs T cell and endothelial cell function, and causes extensive pulmonary damage. Therefore, inhibition of arginase-1 and/or replenishment of arginine may be important in preventing/treating severe COVID-19. Copyright © 2021 Dean, Ochoa, Sanchez-Pino, Zabaleta, Garai, Del Valle, Wyczechowska, Baiamonte, Philbrook, Majumder, Vander Heide, Dunkenberger, Thylur, Nossaman, Roberts, Chapple, Wu, Hicks, Collins, Luke, Johnson, Koul, Rees, Morris, Garcia-Diaz and Ochoa.

    See More

External Sources

  1. DOI: 10.3389/fimmu.2021.695972
  2. PMID: 34341659
  3. PMCID: PMC8324422
  4. WOS: 000679946200001

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel